|
gptkbp:instanceOf
|
antiviral drug
|
|
gptkbp:administeredBy
|
oral
intramuscular injection
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
|
|
gptkbp:ATCCode
|
gptkb:P01BE02
|
|
gptkbp:brand
|
gptkb:Coartem
gptkb:Riamet
|
|
gptkbp:CASNumber
|
71963-77-4
|
|
gptkbp:combines
|
gptkb:lumefantrine
|
|
gptkbp:contraindication
|
hypersensitivity to artemether
|
|
gptkbp:derivedFrom
|
gptkb:artemisinin
|
|
gptkbp:developedBy
|
gptkb:China
|
|
gptkbp:discoveredIn
|
1981
|
|
gptkbp:drugClass
|
antimalarial
|
|
gptkbp:eliminationHalfLife
|
1-3 hours
|
|
gptkbp:hasMolecularFormula
|
C16H26O5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
artemether
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits parasite growth
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
use with caution in first trimester
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
|
|
gptkbp:sideEffect
|
fever
nausea
vomiting
headache
|
|
gptkbp:usedFor
|
treatment of malaria
|
|
gptkbp:usedInCombinationTherapy
|
gptkb:artemether-lumefantrine
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Project_523
|
|
gptkbp:bfsLayer
|
5
|